Company Overview and News

 
Merck shares hit record high after profit jump

2018-04-30 thehindubusinessline
The Merck logo is seen at an office building in Singapore in this file photo. - Reuters

 
Corona Remedies acquires two brands from Abbott

2018-04-02 moneycontrol
City-based pharma firm Corona Remedies today announced the acquisition of Obimet and Thyrocab brands, comprising of 14 product line extensions, from Abbott India.

 
In ₹1,000-crore deal, SEBI buys IDBI Bank’s Mumbai property

2018-02-12 thehindubusinessline
In one of India’s biggest commercial property acquisitions, market regulator SEBI has struck a deal to buy IDBI Bank’s seven-storey office building at the Bandra-Kurla Complex (BKC), Mumbai’s prime business hub.

 
Market Update: Midcap index outshines; Tata Steel, ONGC jump 3-4%; Ashok Leyland hits new 52-week high, SBI falls 3%

2018-02-12 moneycontrol
A new week and a new start - it was a green opening from the Indian indices with the Sensex jumping over 256 points or 0.75 percent in early trade while the Nifty added 73 points or 0.72 percent.

 
Govt stalls plan to cut drug prices after pushback from pharma companies

2018-01-12 business-standard
Ari Altstedter & Abhijit Roy Chowdhury | Bloomberg  Last Updated at January 12, 2018 18:01 IST

 
Market Update: Unitech zooms 20%; HDFC Bank jumps 2%; Vedanta top gainer, Airtel most active

2017-12-08 moneycontrol
The Indian benchmark indices on Friday afternoon were trading on a positive note with the Nifty up 82 points or 0.81 percent while the Sensex added 254 points and was trading at 33203.

 
Market Update: 115 stocks hit new 52-week high on BSE; Maruti top gainer, ICICI Bank up 1%

2017-12-08 moneycontrol
The Indian benchmark indices on Friday afternoon were trading on a positive note with the Nifty up 76 points or 0.75 percent while the Sensex added 241 points and was trading at 33190.

 
Market Update: Maruti hits new record high, Future Consumer zooms 14%; DLF hits 52-week high

2017-12-08 moneycontrol
The Indian benchmark indices on Friday morning were trading on a positive note with the Nifty up 61 points or 0.6 percent while the Sensex added 198 points and was trading at 33151.

 
Market Update: SBI, PNB, YES Bank up 2% as Bank Nifty outperforms; Hero Moto, Wipro top losers

2017-12-05 moneycontrol
The Indian benchmark indices on Tuesday afternoon were still trading on a negative note with the Nifty up 1 point or 0.01 percent while the Sensex shed 25 points and was trading at 32838.

 
Market Update: RIL, Bharti Airtel top Nifty gainers; Eicher Motors down over 2%, Infosys most active

2017-12-05 moneycontrol
The Indian benchmark indices on Tuesday afternoon were still trading on a negative note with the Nifty down 42 points or 0.42 percent while the Sensex shed 141 points and was trading at 32727.

 
Market Update: Infosys, Zee gains 2-3%; Jubilant Food jumps over 5%; UPL, Coal India top losers

2017-12-04 moneycontrol
The Indian benchmark indices on Monday afternoon were trading on a positive note with the Nifty up 10.85 points or 0.11 percent while the Sensex added 52 points and was trading at 32885.

 
Market Update: Biocon hits new 52-week high after jumping 10%; Infosys gains 3%, HDFC, SBI most active

2017-12-04 moneycontrol
The Indian benchmark indices on Monday afternoon were trading on a positive note with the Nifty up 21 points or 0.21 percent while the Sensex added 79 points and was trading at 32912.

 
Abbott India shares surge over 12% on Q2 profit

2017-11-13 moneycontrol
Shares of drug firm Abbott India on Monday soared over 12 percent after the company reported 83.31 percent jump in net profit for the September quarter.

 
Closing Bell: Selling pressure grips Sensex as it ends 281 pts lower; Nifty below 10,250

2017-11-13 moneycontrol
3:30 pm Market at Close: Selling pressure in the final hour of trade dragged the market lower, with the Sensex closing over 250 points lower, while the Nifty closed below 10,250-mark.

 
Abbott India Q2 profit rises 83% to Rs137.52 crore

2017-11-13 livemint
New Delhi: Drug firm Abbott India on Monday reported 83.31% jump in net profit to Rs137.52 crore for the September quarter on account of robust sales.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...